Enveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics Forum

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that Director and CEO, Joseph Tucker, Ph.D., will participate in a panel discussion at Needham's upcoming Virtual Psychedelics Forum. The panel, “Beyond TRD (Treatment-Resistant Depression): Non-Hallucinogens and New Indications,” is scheduled for.